Clinical Research Directory
Browse clinical research sites, groups, and studies.
Using Advanced CT Scans and Blood Markers to Better Understand Heart Damage and Recovery After a Heart Attack
Sponsor: Instituto de Investigación Biomédica de Salamanca
Summary
Acute myocardial infarction with ST-segment elevation (STEMI) remains a leading cause of morbidity and mortality worldwide. Although advances in reperfusion therapy have reduced early mortality, many patients later develop adverse ventricular remodeling (AVR), which increases the risk of heart failure and cardiovascular death. Current imaging methods, such as echocardiography and cardiac magnetic resonance (CMR), provide valuable prognostic information but have limitations in availability, cost, and their ability to predict AVR early and individually. Spectral computed tomography (CT) is an emerging imaging technique that can characterize myocardial tissue, quantify infarct size, assess microvascular obstruction, and detect complications, with lower contrast and radiation requirements compared to conventional CT. In parallel, circulating microRNAs (miRNAs) have been identified as stable and non-invasive biomarkers that reflect key biological processes in post-infarction remodeling. Several miRNAs are linked to fibrosis, apoptosis, and ventricular remodeling, suggesting their potential to complement imaging findings in risk prediction. This study proposes a multicenter, prospective cohort of patients with STEMI and reduced left ventricular function to evaluate whether combining spectral CT tissue characterization with serum miRNA profiling can improve early prediction of AVR. The main objective is to generate and validate a multiparametric prognostic model integrating imaging and molecular biomarkers to identify high-risk patients who may benefit from closer monitoring and tailored therapeutic strategies.
Official title: SPEctral CT and miRna In Acute Myocardial Infarction for Comprehensive Adverse Remodeling Evaluation
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
95
Start Date
2026-01
Completion Date
2028-12
Last Updated
2025-12-10
Healthy Volunteers
No
Conditions
Interventions
Blood analysis, spectral CT scan and cardiac magnetic resonance imaging (CMR) study
After providing informed consent, patients will undergo blood sampling, a spectral CT scan scheduled between the 3rd and 7th day of hospitalization (acute phase), and a cardiac magnetic resonance imaging (CMR) study performed within a maximum of 72 hours from the CT.
Blood analysis and spectral CT study
Patients who meet the inclusion criteria for the control group will be invited to participate in the study. They will undergo blood sampling and the planned spectral CT study, including a late iodine enhancement acquisition.
Locations (5)
Centro Nacional de Investigaciones Cardiovasculares (CNIC)
Madrid, Spain
Hospital La Princesa
Madrid, Spain
Hospital Ramón y Cajal
Madrid, Spain
Complejo Asistencial Universitario de Salamanca
Salamanca, Spain
Hospital Clínico Universitario de Valencia
Valencia, Spain